Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Biotest AG
  6. News
  7. Summary
    BIO3   DE0005227235

BIOTEST AG

(BIO3)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : Biotest AG: Biotest accelerates fibrinogen phase III study with additional patient group

04/07/2021 | 01:02am EDT
DGAP-News: Biotest AG / Key word(s): Study 
Biotest AG: Biotest accelerates fibrinogen phase III study with additional patient group 
2021-04-07 / 07:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
PRESS RELEASE 
Biotest accelerates fibrinogen phase III study with additional patient group 
- First patient of this group treated successfully 
- Important milestone for acceleration of the clinical development program for Fibrinogen 
- Excellent efficacy and tolerability confirmed 
- Results are the basis for the marketing authorization in Europe 
 
Dreieich, 7 April 2020. Biotest AG announces today that the first patient with pseudomyxoma peritonei (PMP) has been 
treated as part of the ongoing phase III trial for the treatment of severe bleeding in the case of acquired fibrinogen 
deficiency (AdFIrst study no. 995). PMP is a rare malignant and painful tumor in the abdominal cavity. During a 
surgical procedure, the tumor tissue is removed, which could lead to high blood loss and thus to the loss of the body's 
own fibrinogen. In order to compensate the fibrinogen deficiency and to effectively stop bleeding, Biotest has 
developed the fibrinogen concentrate BT524. The efficacy and tolerability of BT524 are investigated in the AdFIrst 
study (Adjusted Fibrinogen Replacement Strategy) in comparison to the standard therapy, consisting of blood plasma 
preparations (frozen fresh plasma and cryoprecipitate). 
The AdFIrst study is a prospective, randomized, active-controlled, multicenter phase III study that investigates the 
efficacy and tolerability of the fibrinogen concentrate BT524 in patients with acquired fibrinogen deficiency. Patients 
who have a high level of blood loss during a planned spinal or abdominal surgery are included. 
With the AdFIrst study in acquired fibrinogen deficiency, Biotest is further expanding its development program for the 
fibrinogen concentrate BT524. The phase I/III study no. 984 for the treatment of patients with congenital fibrinogen 
deficiency was already completed successfully in May 2020. The results of both studies will serve as the basis for the 
marketing authorization of fibrinogen concentrate BT524 for the treatment of patients with congenital and acquired 
fibrinogen deficiency. 
About Biotest's fibrinogen concentrate 
The newly developed manufacturing process of the fibrinogen concentrate leads to high-purity fibrinogen with a defined 
concentration, high level of viral safety and good solubility. 
About study no. 995 / 
The AdFIrst study is a prospective, active-controlled, multicentre phase III study investigating the efficacy and 
safety of the fibrinogen concentrate BT524 in patients with acquired fibrinogen deficiency. Patients who have high 
blood loss during planned spinal and abdominal surgery are randomised 1:1 to treatment with BT524 or FFP/ 
Cryoprecipitate. To evaluate the efficacy, further blood loss is compared between the both treatment options. Further 
information about the study design can be found at www.clinicaltrialsregister.eu (EudraCT number: 2017-001163-20). 
About fibrinogen and fibrinogen deficiency 
Fibrinogen is a blood clotting factor that is produced in the liver. It plays a key role in primary haemostasis 
(stopping blood loss from bleeding wounds) and wound healing. In case of a lack or shortage of fibrinogen blood's 
ability to clot is impaired which leads to a much greater risk of bleeding and delayed haemostasis. To date, these 
patients have been treated mainly with fresh frozen plasma (FFP), but this contains variable amounts of fibrinogen and 
must be thawed prior to treatment. The defined amount of fibrinogen in the fibrinogen concentrate now allows a 
tailor-made, patient specific and highly effective therapy. 
About Biotest 
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical 
and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, 
haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin 
based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more 
than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on 
the German stock exchange. 
IR contact 
Dr Monika Buttkereit 
Phone: +49-6103-801-4406 
Mail: investor_relations@biotest.de 
PR contact 
Dirk Neumüller 
Phone: +49-6103-801-269 
Mail: pr@biotest.com 
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com 
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201 
Preference shares: securities' ID No. 522723; ISIN DE0005227235 
Listing: Frankfurt (Prime Standard) 
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate 
Disclaimer 
This document contains forward-looking statements on overall economic development as well as on the business, earnings, 
financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, 
estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that 
could result in significant deviation of actual developments from expected developments. The forward-looking statements 
are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes 
no obligation to do so. 
=---------------------------------------------------------------------------------------------------------------------- 
2021-04-07 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Biotest AG 
              Landsteinerstraße 5 
              63303 Dreieich 
              Germany 
Phone:        0 61 03 - 8 01-0 
Fax:          0 61 03 - 8 01-150 
E-mail:       investor_relations@biotest.de 
Internet:     http://www.biotest.de 
ISIN:         DE0005227235, DE0005227201 
WKN:          522723, 522720 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1181473 
 
End of News   DGAP News Service 
=------------ 

1181473 2021-04-07

(END) Dow Jones Newswires

April 07, 2021 01:01 ET (05:01 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
BIOTEST AG 10.42% 39.2 Delayed Quote.39.50%
PEUGEOT INVEST -2.38% 114.8 Real-time Quote.21.35%
All news about BIOTEST AG
09/17GLOBAL MARKETS LIVE : Ryanair, Ford, Apple, Alphabet, Gap...
09/17BIOTEST AG : Takeover Offer: Grifols S.A. to make a voluntary public takeover of..
DJ
09/17GRIFOLS S A : Further Expands Plasma Capabilities With $1.3 Billion Biotest Deal
MT
09/17GRIFOLS S A : to Acquire Controlling Stake in German Rival Biotest
MT
09/17European shares fall for third week in a row, miners worst hit
RE
09/17GRIFOLS S A : To Buy Majority Stake In Germany's Biotest For $1.3 Billion
MT
09/17GRIFOLS S A : Spain's Grifols to buy rival Biotest for up to $1.9 bln
RE
09/17DGAP-WPÜG : Takeover Offer / Target company: Biotest Aktiengesellschaft; Bidder:..
DJ
09/16GRIFOLS S A : Could Soon Buy Germany's Biotest from Chinese Investor
MT
09/15BIOTEST AG : Biotest announces the new Renate & Hans Schleussner Award for scien..
EQ
More news
Financials
Sales 2021 509 M 597 M 597 M
Net income 2021 -21,1 M -24,8 M -24,8 M
Net Debt 2021 446 M 523 M 523 M
P/E ratio 2021 -73,4x
Yield 2021 0,10%
Capitalization 1 642 M 1 928 M 1 925 M
EV / Sales 2021 4,10x
EV / Sales 2022 3,84x
Nbr of Employees 1 963
Free-Float 55,1%
Chart BIOTEST AG
Duration : Period :
Biotest AG Technical Analysis Chart | BIO3 | DE0005227235 | MarketScreener
Technical analysis trends BIOTEST AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 39,20 €
Average target price 38,43 €
Spread / Average Target -1,98%
EPS Revisions
Managers and Directors
Michael Ramroth Chairman-Management Board & CFO
Rolf K. Hoffmann Chairman-Supervisory Board
Christian Polus Head-Information Technology
Georg Floß Chief Operations Officer
Oliver Hein Head-Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOTEST AG39.50%1 928
CSL LIMITED9.25%102 521
WUXI BIOLOGICS (CAYMAN) INC.19.75%67 077
SAMSUNG BIOLOGICS CO.,LTD.12.95%52 329
BIOGEN INC.22.39%44 738
ALEXION PHARMACEUTICALS, INC.0.00%40 336